Vaccines Market Trends, Analysis & Forecast, 2025-2034

Vaccines Market-By Vaccine Type, By Disease Type, By Age Group, By End Use - Global Forecast, 2025-2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 360&deg; synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional

2.2.2&nbsp;&nbsp;&nbsp; Vaccine type

2.2.3&nbsp;&nbsp;&nbsp; Disease type

2.2.4&nbsp;&nbsp;&nbsp; Age group

2.2.5&nbsp;&nbsp;&nbsp; End use

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising incidence of infectious disease

3.2.1.2&nbsp;&nbsp;&nbsp; Growing immunization coverage programs

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing pediatric population in developing economies

3.2.1.4&nbsp;&nbsp;&nbsp; Advancements in vaccine formulation and production efficiency

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Stringent regulatory approval processes

3.2.2.2&nbsp;&nbsp;&nbsp; High cost of storage and transportation of vaccine

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Expanding public-private partnerships for vaccine distribution

3.2.3.2&nbsp;&nbsp;&nbsp; Growing focus on combination vaccines

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Technology landscape

3.5&nbsp;&nbsp;&nbsp; Pipeline analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.7&nbsp;&nbsp;&nbsp; Future market trends

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Mergers and acquisitions

4.6.2&nbsp;&nbsp;&nbsp; Partnerships and collaborations

4.6.3&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Vaccine Type, 2021-2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Subunit vaccines

5.2.1&nbsp;&nbsp;&nbsp; Recombinant vaccines

5.2.2&nbsp;&nbsp;&nbsp; Conjugate vaccines

5.2.3&nbsp;&nbsp;&nbsp; Polysaccharide vaccines

5.3&nbsp;&nbsp;&nbsp; Toxoid vaccines

5.4&nbsp;&nbsp;&nbsp; Inactivated vaccines

5.5&nbsp;&nbsp;&nbsp; Live attenuated vaccines

5.6&nbsp;&nbsp;&nbsp; Other vaccine types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2021-2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Viral diseases

6.2.1&nbsp;&nbsp;&nbsp; Hepatitis

6.2.2&nbsp;&nbsp;&nbsp; Influenza

6.2.3&nbsp;&nbsp;&nbsp; HPV

6.2.4&nbsp;&nbsp;&nbsp; Measles, mumps, and rubella (MMR)

6.2.5&nbsp;&nbsp;&nbsp; Rotavirus

6.2.6&nbsp;&nbsp;&nbsp; Herpes zoster

6.2.7&nbsp;&nbsp;&nbsp; Covid-19

6.2.8&nbsp;&nbsp;&nbsp; Other viral diseases

6.3&nbsp;&nbsp;&nbsp; Bacterial diseases

6.3.1&nbsp;&nbsp;&nbsp; Meningococcal diseases

6.3.2&nbsp;&nbsp;&nbsp; Pneumococcal diseases

6.3.3&nbsp;&nbsp;&nbsp; DPT

6.3.4&nbsp;&nbsp;&nbsp; Other bacterial diseases

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2021-2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Pediatric

7.3&nbsp;&nbsp;&nbsp; Adult

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals

8.2.1&nbsp;&nbsp;&nbsp; Public

8.2.2&nbsp;&nbsp;&nbsp; Private

8.3&nbsp;&nbsp;&nbsp; Specialty clinics

8.4&nbsp;&nbsp;&nbsp; Other end use

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; AstraZeneca

10.2&nbsp;&nbsp;&nbsp; Bharat Biotech

10.3&nbsp;&nbsp;&nbsp; Biofarma

10.4&nbsp;&nbsp;&nbsp; CSL Seqirus

10.5&nbsp;&nbsp;&nbsp; Emergent Biosolutions

10.6&nbsp;&nbsp;&nbsp; GlaxoSmithKline (GSK)

10.7&nbsp;&nbsp;&nbsp; Haffkine Bio-Pharmaceutical

10.8&nbsp;&nbsp;&nbsp; Merck

10.9&nbsp;&nbsp;&nbsp; Moderna

10.10&nbsp;&nbsp;&nbsp; Novavax

10.11&nbsp;&nbsp;&nbsp; Pfizer

10.12&nbsp;&nbsp;&nbsp; Sanofi

10.13&nbsp;&nbsp;&nbsp; Serum Institute of India

10.14&nbsp;&nbsp;&nbsp; Sinovac

10.15&nbsp;&nbsp;&nbsp; Valneva

10.16&nbsp;&nbsp;&nbsp; VBI Vaccines

&nbsp;&nbsp;&nbsp;

Vaccines Market

Request Discount

Industries

Information

Link

Global Headquarters